Similarly, the COMBI-AD trial investigated the effects of dabrafenib (a BRAF inhibitor) plus trametinib (a MEK inhibitor) on patients with resected BRAFV600-mutant stage III melanoma, including those with in-transit metastases. This evidence concerns the gene MAP2K7 and melanoma.